Literature DB >> 7217302

Determination of bufuralol and its major metabolites in plasma by high-performance liquid chromatography.

P Haefelfinger.   

Abstract

A high-performance liquid chromatographic method for the determination of bufuralol, a benzofuran analogue, in plasma is described. The unchanged drug, the major metabolites and an internal standard are extracted from plasma, purified by back-extraction steps and thereafter separated using a reversed-phase liquid chromatographic system. The detection is carried out by means of a fluorescence detector and an UV detector connected in series. The sensitivity of the assay for the unchanged drug and the major metabolite is about 1 ng/ml plasma using a 0.5 ml specimen per analysis and the relative standard deviation of the whole assay lies in the range +/- 4-5%. The procedure was successfully used to determine plasma levels in volunteers following a single oral dose of 40 mg of bufuralol. The results obtained using the new high-performance liquid chromatographic method were compared with those determined by another method which combines gas chromatography with mass fragmentography, and it was found that these two sets of results coincided quite well.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7217302     DOI: 10.1016/s0378-4347(00)84318-2

Source DB:  PubMed          Journal:  J Chromatogr


  5 in total

1.  Relationship between pharmacokinetic and pharmacodynamic behaviour of bufuralol and its metabolite Ro 3-7410 in hypertensive patients.

Authors:  M Eckert; G Cocco; C Strozzi; P Heizmann; C Sfrisi
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

2.  Contribution of the genetic status of oxidative metabolism to variability in the plasma concentrations of beta-adrenoceptor blocking agents.

Authors:  P Dayer; L Balant; A Küpfer; F Courvoisier; J Fabre
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

3.  Defective hydroxylation of bufuralol associated with side-effects of the drug in poor metabolisers.

Authors:  P Dayer; A Kubli; A Kupfer; F Courvoisier; L Balant; J Fabre
Journal:  Br J Clin Pharmacol       Date:  1982-05       Impact factor: 4.335

4.  Effect of oxidative polymorphism (debrisoquine/sparteine type) on hepatic first-pass metabolism of bufuralol.

Authors:  P Dayer; L Balant; A Kupfer; R Striberni; T Leemann
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

5.  The genetic control of bufuralol metabolism in man.

Authors:  P Dayer; L Balant; F Courvoisier; A Kupfer; A Kubli; A Gorgia; J Fabre
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1982 Jan-Mar       Impact factor: 2.441

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.